DeepMed Research

United Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1996-01-01

Employees: -

Market Cap: $15.5B

Website: http://www.unither.com

Clinical Trials

Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

Terminated

Conditions: Neuroblastoma

Interventions: Drug: Dinutuximab

First Posted Date: 2016-02-26

Last Posted Date: 2019-08-05

Lead Sponsor: United Therapeutics

Target Recruit Count: 13

Registration Number: NCT02693171

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 15 locations

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Phase 2

Terminated

Conditions: Pulmonary Hypertension
Interstitial Lung Disease
Combined Pulmonary Fibrosis and Emphysema

Interventions: Drug: Inhaled Treprostinil

First Posted Date: 2015-12-17

Last Posted Date: 2022-12-02

Lead Sponsor: United Therapeutics

Target Recruit Count: 243

Registration Number: NCT02633293

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 89 locations

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

Phase 2

Completed

Conditions: Pulmonary Hypertension
Combined Pulmonary Fibrosis and Emphysema
Interstitial Lung Disease

Interventions: Drug: Placebo
Drug: Inhaled Treprostinil

First Posted Date: 2015-12-15

Last Posted Date: 2022-07-27

Lead Sponsor: United Therapeutics

Target Recruit Count: 326

Registration Number: NCT02630316

Locations: 🇺🇸
Wellstar Medical Group - Pulmonary Medicine, Marietta, Georgia, United States
🇺🇸
Johns Hopkins University Pulmonary and Critical Care Medicine, Baltimore, Maryland, United States
🇺🇸
Penn Medicine University City, Philadelphia, Pennsylvania, United States

and more 94 locations

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Phase 2

Withdrawn

Conditions: Pulmonary Hypertension
Pulmonary Fibrosis

Interventions: Drug: Oral treprostinil

First Posted Date: 2015-11-11

Last Posted Date: 2016-02-09

Lead Sponsor: United Therapeutics

Registration Number: NCT02603068

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
CLC Pulmonary Hypertension Clinic Division of Pulmonary, Allergy and Critical Care Medicine UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸
Banner University Medical Center Phoenix Advanced Lung Disease, Phoenix, Arizona, United States

and more 4 locations

Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: UT-15C
Other: ethanol

First Posted Date: 2014-12-17

Last Posted Date: 2015-03-24

Lead Sponsor: United Therapeutics

Target Recruit Count: 32

Registration Number: NCT02318758

Locations: 🇺🇸
PPD International, Austin, Texas, United States

Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

Phase 2

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Ralinepag

First Posted Date: 2014-10-31

Last Posted Date: 2021-12-22

Lead Sponsor: United Therapeutics

Target Recruit Count: 45

Registration Number: NCT02279745

Locations: 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇦🇺
St Vincent's Hospital, Fitzroy, Victoria, Australia
🇧🇬
Multiprofile Hospital for Active Treatment "National Heart Hospital" EAD, Clinic of Cardiology, Sofia, Bulgaria

and more 43 locations

Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension

Phase 2

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: APD811
Drug: Placebo

First Posted Date: 2014-10-30

Last Posted Date: 2020-07-14

Lead Sponsor: United Therapeutics

Target Recruit Count: 61

Registration Number: NCT02279160

Locations: 🇺🇸
UT Southwestern, Dallas, Texas, United States
🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

and more 31 locations

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

Phase 2

Completed

Conditions: PAH

Interventions: Drug: oral treprostinil

First Posted Date: 2014-10-28

Last Posted Date: 2025-03-30

Lead Sponsor: United Therapeutics

Target Recruit Count: 32

Registration Number: NCT02276872

Locations: 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States

and more 6 locations

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

Phase 2

Terminated

Conditions: Persistent Pulmonary Hypertension of the Newborn

Interventions: Drug: IV Remodulin
Drug: Placebo

First Posted Date: 2014-10-10

Last Posted Date: 2024-03-05

Lead Sponsor: United Therapeutics

Target Recruit Count: 42

Registration Number: NCT02261883

Locations: 🇺🇸
Stanford Children's Hospital, Palo Alto, California, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 11 locations

Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers

Phase 1

Withdrawn

Conditions: PAH

Interventions: Drug: TransCon PEG treprostinil

First Posted Date: 2014-05-29

Last Posted Date: 2014-08-07

Lead Sponsor: United Therapeutics

Registration Number: NCT02149095

Locations: 🇺🇸
PPD Development, Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy